US Stock MarketDetailed Quotes

SLNO Soleno Therapeutics

Watchlist
  • 57.7800
  • +3.1500+5.77%
Close Nov 22 16:00 ET
  • 59.5900
  • +1.8100+3.13%
Post 20:01 ET
2.49BMarket Cap-20709P/E (TTM)

About Soleno Therapeutics Company

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Company Profile

SymbolSLNO
Company NameSoleno Therapeutics
Listing DateNov 13, 2014
Founded1999
CEODr. Anish Bhatnagar, M.D.
MarketNASDAQ
Employees42
Fiscal Year Ends12-31
Address100 Marine Parkway,Suite 400
CityRedwood City
ProvinceCalifornia
CountryUnited States of America
Zip Code94065
Phone1-650-213-8444

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Anish Bhatnagar, M.D.
  • President, Chief Executive Officer, Chief Operating Officer and Director
  • 4.12M
  • Meredith S. Manning
  • Chief Commercial Officer
  • --
  • James H. Mackaness
  • Chief Financial Officer and Principal Accounting Officer
  • 1.21M
  • Patricia C. Hirano
  • Senior Vice President, Regulatory Affairs
  • 1.03M
  • Kristen Yen
  • Senior Vice President, Clinical Operations
  • --
  • Dr. Michael Huang, M.D.
  • Senior Vice President, Clinical Development
  • --
  • Dawn Carter Bir
  • Director
  • --
  • Matthew Pauls, J.D.,M.B.A.
  • Lead Independent Director
  • 70.53K
  • William G. Harris
  • Independent Director
  • 111.87K
  • Dr. Andrew Sinclair, PhD
  • Independent Director
  • 51.87K
  • Dr. Birgitte Volck, M.D.,PhD
  • Independent Director
  • 102.87K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data